Science and Research

Response to: ' Correspondence on 'Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension'' by Iudici et al

  • Grünig, E.
  • Benjamin, N.
  • Xanthouli, P.
  • Jordan, S.
  • Milde, N.
  • Marra, A.
  • Blank, N.
  • Egenlauf, B.
  • Gorenflo, M.
  • Harutyunova, S.
  • Lorenz, H. M.
  • Nagel, C.
  • Theobald, V.
  • Lichtblau, M.
  • Berlier, C.
  • Ulrich, S.
  • Distler, O.

Keywords

  • epidemiology
  • hypertension
  • scleroderma
  • systemic
  • personal fees from Bayer, outside the submitted work. NB has received consulting
  • fees, speaker fees and/or honoraria from MSD, GSK, Actelion and Bayer Vital. BE
  • received travel fees, consulting fees, speaking fees and/or honoraria from Actelion,
  • MSD, Bayer and OMT (less than US$10 000 each). MG serves on an advisory Board for
  • Bayer AG and receives lecture fees from Pfizer, MSD and Actelion Pharmaceuticals. SH
  • has received personal fees from Bayer, MSD, Actelion and GSK, outside the submitted
  • work. H-ML has received consulting fees, speaking fees and/or honoraria from AbbVie,
  • BMS, Pfizer, Cellgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag,
  • AstraZeneca and Lilly (less than US$10 000 each) and research support from AbbVie,
  • MSD, BMS, Cellgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag,
  • AstraZeneca, Lilly, Baxter, SOBI, Biogen, Actelion, Bayer Vital, Shire, Octapharm,
  • Sanofi, Hexal, Mundipharm and Thermo Fisher. CN has received consulting fees,
  • speaking fees and/or honoraria from Actelion, MSD, Boehringer, Novartis, Bayer and
  • AstraZeneca (less than US$10 000 each). CB received travel support from Actelion SA
  • and Orpha Swiss and speakers’ fee from MSD. SU received grants from the Swiss
  • National Science foundation and the Zurich Lung League, travel support and speakers’
  • fees from Actelion SA, Switzerland, Bayer SA, Germany, MSD, Switzerland and Orpha
  • Swiss. EG has received grants and personal fees from Actelion, Bayer AG and MSD
  • grants from GSK, Novartis and United Therapeutics
  • and personal fees from SCOPE,
  • OrPha Swiss GmbH and Zurich Heart House (less than US$10 000 each). NB received
  • speaker fees from Actelion pharmaceuticals, Bayer HealthCare and MSD. OD has
  • received grants and personal fees from research consultancies from AM, Acceleron
  • Pharma, Amgen, AnaMar, Bayer, Beacon Discovery, Boehringer Ingelheim, Catenion, CSL
  • Behring, ChemomAb, Ergonex, GSK, Inventiva, Italfarmaco, iQone, iQvia, Lilly, medac,
  • Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Roche, Sanofi, Blade
  • Therapeutics, Glenmark Pharmaceuticals, Target Bio Science and UCB, outside the
  • submitted work, to investigate potential treatments of scleroderma and its
  • complications. In addition, OD has a patent mir-29 for the treatment of systemic
  • sclerosis issued (US8247389, EP2331143).
Publication details
DOI: 10.1136/annrheumdis-2020-219597
Journal: Ann Rheum Dis
Work Type: Original
Location: TLRC
Disease Area: PH
Partner / Member: Thorax, UKHD
Access-Number: 33328252

DZL Engagements

chevron-down